X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
BT8009 is an investigational Bicycle Toxin Conjugate (BTC™) targeting Nectin-4, a well-validated tumor antigen with elevated levels of expression in multiple tumor types, including bladder (urothelial) cancer.
Lead Product(s): BT8009,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT8009
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 11, 2023
Details:
The net proceeds will be used for the development of BT5528, a second-generation Bicycle Toxin Conjugate (BTC®) targeting EphA2, in patients with advanced solid tumors.
Lead Product(s): BT5528,Nivolumab
Therapeutic Area: Oncology Product Name: BT5528
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $230.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 18, 2023
Details:
Bicycle plans to use the net proceeds from the offering to fund the continued development of its proprietary pipeline including, BT8009, a Nectin-4 targeting Bicycle Toxin Conjugate, being developed for the treatment of Solid Tumours.
Lead Product(s): BT8009,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT8009
Highest Development Status: Phase I/ Phase IIProduct Type: Peptide
Partner/Sponsor/Collaborator: Goldman Sachs & Co.
Deal Size: $200.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering July 12, 2023
Details:
The collaboration will leverage Bicycle Therapeutic’s proprietary bicyclic peptides technology (Bicycle®), for the discovery and development, manufacture, and commercialize Bicycle radioconjugates for multiple agreed upon oncology targets.
Lead Product(s): Bicyclic Peptide-based Radio Conjugate
Therapeutic Area: Oncology Product Name: Undislcosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $1,745.0 million Upfront Cash: $45.0 million
Deal Type: Collaboration May 10, 2023
Details:
Under the terms of the collaboration, Bicycle Therapeutics and German Cancer Research Center will develop and discover Bicycle® radio conjugates (BRCs) for a range of oncology targets.
Lead Product(s): Bicyclic Peptide-based Radio Conjugate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: German Cancer Research Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration May 04, 2023
Details:
Bicycle and Novartis will collaborate on the discovery and development of Bicycle® radio-conjugates (BRCs) for multiple targeted radioligand therapies in oncology using Bicycle's proprietary bicyclic peptide technology.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Peptide
Partner/Sponsor/Collaborator: Novartis Pharmaceuticals Corporation
Deal Size: $1,750.0 million Upfront Cash: $50.0 million
Deal Type: Collaboration March 28, 2023
Details:
BT8009 is a monotherapy which targets Nectin-4, a cell adhesion molecule from the Nectin and Nectin-like family, which has been shown to be overexpressed in tumor cells and is believed to play a role in tumor cell growth and proliferation.
Lead Product(s): BT8009,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT8009
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 14, 2023
Details:
BT8009 is a monotherapy which targets Nectin-4, a cell adhesion molecule from the Nectin and Nectin-like family, which has been shown to be overexpressed in tumor cells and is believed to play a role in tumor cell growth and proliferation.
Lead Product(s): BT8009,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT8009
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 11, 2023
Details:
BT8009 (Bicyclic Peptide) is a monotherapy for the treatment of adult patients with previously treated locally advanced or metastatic urothelial cancer. BT8009, targets Nectin-4 protein that is over expressed in urothelial cancer and other solid tumors.
Lead Product(s): BT8009,Pembrolizumab
Therapeutic Area: Oncology Product Name: BT8009
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
Details:
BT7480 is a novel, fully synthetic Bicycle tumor-targeted immune cell agonist® (Bicycle TICA™) that contains three Bicycles. One targets Nectin-4 and the others binds to and agonize CD137.
Lead Product(s): BT7480,Nivolumab
Therapeutic Area: Oncology Product Name: BT7480
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
